The goal is to discover and develop novel bispecific antibodies to gamma-delta T cells for the treatment of cancer.
The development timeline for Inovio Pharmaceuticals' coronavirus vaccine candidate is discussed in an H.C. Wainwright & Co. report.
Immunologist Michelle McMurry-Heath is Selected for Her Global Leadership and Commitment to Innovation and Patients Former FDA Official Will Succeed Industry Leader Jim Greenwood on June ...
Kate Bingham has been appointed chair of the UK’s Vaccine Taskforce
By 2024, the biotech sector could rocket to $775 billion with plenty of long-term growth catalysts. And that's great news for biotech stocks.
The company announced that one of its antibodies, STI-1499, has shown 100% inhibition of SARS-CoV-2 in laboratory tests.
Moderna said its early-stage human trial for a coronavirus vaccine produced Covid-19 antibodies in all participants, sending its shares surging.